Pro-life CEO warns of FDA nominee scrutiny
The article discusses President Trump's FDA nominee, Dr. Heidi Overton, and her potential to scrutinize mifepristone, an abortion drug. Advocates believe she may impose tighter safety regulations, citing concerns about its dangers and adverse events, while her confirmation process is upcoming. The ongoing safety review by the FDA aims to determine whether the drug should remain available, with some pro-life officials advocating for its removal from the market.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)